Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.

Saleri N, Dembélé SM, Villani P, Carvalho AC, Cusato M, Bonkoungou V, Nacanabo R, Kouanda S, Comelli M, Regazzi M, Matteelli A.

J Antimicrob Chemother. 2012 Feb;67(2):469-72. doi: 10.1093/jac/dkr445. Epub 2011 Oct 25.

PMID:
22028201
2.

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.

Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, Colomer J, Lopez-Colomes JL, Crespo M, Falcó V, Ocaña I, Pahissa A.

J Antimicrob Chemother. 2007 Apr;59(4):690-7. Epub 2007 Feb 16.

PMID:
17307771
3.

Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.

Matteelli A, Saleri N, Villani P, Bonkoungou V, Carvalho AC, Kouanda S, Sanou MJ, Simporé J, Monno L, Carosi G, Regazzi M, Dembele M.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):64-9.

PMID:
19731452
4.

Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.

Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C, Chen M, Zhou L, Zhao W, Fu L, Lu Y.

Clin Ther. 2013 Feb;35(2):161-8. doi: 10.1016/j.clinthera.2013.01.003.

PMID:
23410999
5.

Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.

Semvua HH, Mtabho CM, Fillekes Q, van den Boogaard J, Kisonga RM, Mleoh L, Ndaro A, Kisanga ER, van der Ven A, Aarnoutse RE, Kibiki GS, Boeree MJ, Burger DM.

Antivir Ther. 2013;18(1):105-13. doi: 10.3851/IMP2413. Epub 2012 Oct 5.

PMID:
23043067
6.

Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.

Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R.

Int J Tuberc Lung Dis. 2016 May;20(5):666-72. doi: 10.5588/ijtld.15.0288.

PMID:
27084822
7.

Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.

Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Likanonsakul S, Ruxrungtham K.

Clin Infect Dis. 2006 Jul 15;43(2):253-5. Epub 2006 Jun 12.

PMID:
16779754
8.

Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.

Rolla VC, da Silva Vieira MA, Pereira Pinto D, Lourenço MC, de Jesus Cda S, Gonçalves Morgado M, Ferreira Filho M, Werneck-Barroso E.

Clin Drug Investig. 2006;26(8):469-79.

PMID:
17163279
9.

Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.

Prasitsuebsai W, Cressey TR, Capparelli E, Vanprapar N, Lapphra K, Chokephaibulkit K.

Pediatr Infect Dis J. 2012 Apr;31(4):389-91. doi: 10.1097/INF.0b013e3182401c41.

PMID:
22146740
10.

Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.

Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson US.

Eur J Clin Pharmacol. 2009 Jan;65(1):71-80. doi: 10.1007/s00228-008-0481-y. Epub 2008 Aug 27.

PMID:
18751690
11.

Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.

Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.

Int J Clin Pharmacol Ther. 2002 Oct;40(10):474-81.

PMID:
12395981
12.

Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.

van Oosterhout JJ, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T, Burger DM, Zijlstra EE.

Antivir Ther. 2007;12(4):515-21.

PMID:
17668560
13.

Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7. doi: 10.1128/AAC.05429-11. Epub 2011 Oct 3.

14.

Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.

Verhagen LM, López D, Hermans PW, Warris A, de Groot R, García JF, de Waard JH, Aarnoutse RE.

Trop Med Int Health. 2012 Dec;17(12):1449-56. doi: 10.1111/tmi.12003. Epub 2012 Oct 24.

15.

Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.

Matteelli A, Villani P, Carvalho AC, El-Hamad I, Cusato M, Apostoli A, Marcantoni C, Calabresi A, Dal Zoppo S, Bigoni S, Regazzi M.

J Antimicrob Chemother. 2012 Oct;67(10):2470-3. doi: 10.1093/jac/dks218. Epub 2012 Jun 7.

PMID:
22678727
16.

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

López-Cortés LF, Ruiz-Valderas R, Viciana P, Alarcón-González A, Gómez-Mateos J, León-Jimenez E, Sarasanacenta M, López-Pua Y, Pachón J.

Clin Pharmacokinet. 2002;41(9):681-90.

PMID:
12126459
17.
18.

Tuberculosis and HIV co-infection: a practical therapeutic approach.

Breen RA, Swaden L, Ballinger J, Lipman MC.

Drugs. 2006;66(18):2299-308. Review.

PMID:
17181373
19.

Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.

Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S.

Clin Infect Dis. 2007 Jan 1;44(1):141-4. Epub 2006 Nov 21.

PMID:
17143831
20.

Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.

Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, Maartens G.

J Antimicrob Chemother. 2008 Feb;61(2):389-93. Epub 2007 Dec 19.

PMID:
18096560

Supplemental Content

Support Center